MA28335A1 - Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes - Google Patents

Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes

Info

Publication number
MA28335A1
MA28335A1 MA29206A MA29206A MA28335A1 MA 28335 A1 MA28335 A1 MA 28335A1 MA 29206 A MA29206 A MA 29206A MA 29206 A MA29206 A MA 29206A MA 28335 A1 MA28335 A1 MA 28335A1
Authority
MA
Morocco
Prior art keywords
agonists
vpac2
receptor
hypophysic
pacap
Prior art date
Application number
MA29206A
Other languages
English (en)
Inventor
Kevin Clairmont
Kevin J Lumb
Thomas Buckholz
Arthur I Salhanick
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MA28335A1 publication Critical patent/MA28335A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

La présente invention fournit de nouveaux peptides qui agissent in vivo comme des agonistes du récepteur VPAC2. Il a été montré que ces polypeptides sécrétagogues de l'insuline abaissent la glycémie in vivo après une provocation par le glucose. Les polypeptides de la présente invention sont par ailleurs stables dans une formulation et ont des demi-vies prolongées. Les peptides de la présente invention offrent un traitement aux patients présentant une sécrétion d'insuline endogène réduite, par exemple les diabétiques de type 2. L'invention concerne en outre un procédé de traitement d'une maladie métabolique chez un mammifère comprenant l'administration d'une quantité efficace du point de vue thérapeutique desdits peptides audit mammifère.
MA29206A 2004-01-27 2006-07-24 Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes MA28335A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53955004P 2004-01-27 2004-01-27
US56649904P 2004-04-29 2004-04-29

Publications (1)

Publication Number Publication Date
MA28335A1 true MA28335A1 (fr) 2006-12-01

Family

ID=34830483

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29206A MA28335A1 (fr) 2004-01-27 2006-07-24 Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes

Country Status (13)

Country Link
US (1) US20090143283A1 (fr)
EP (1) EP1713493A4 (fr)
JP (1) JP2007519739A (fr)
KR (1) KR20070009554A (fr)
AU (1) AU2005208911A1 (fr)
BR (1) BRPI0507177A (fr)
CA (1) CA2554475A1 (fr)
EC (1) ECSP066793A (fr)
IL (1) IL176705A0 (fr)
MA (1) MA28335A1 (fr)
NO (1) NO20063801L (fr)
RU (1) RU2006130691A (fr)
WO (1) WO2005072385A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2575101A1 (fr) * 2004-06-12 2005-12-29 Bayer Pharmaceuticals Corporation Pegylation d'agonistes vis-a-vis du recepteur 2 (vpac2) de peptide intestinal vaso-actif (vip)/peptide d'activation d'adenylate cyclase pituitaire (pacap) et procedes d'utilisation
CA2607273A1 (fr) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Agonistes du recepteur (vpac2) du peptide activant l'adenylate cyclase hypophysaire (pacap) et leurs procedes pharmacologiques d'utilisation
CN101296708B (zh) * 2005-10-26 2011-12-07 伊莱利利公司 选择性vpac2受体肽激动剂
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
WO2014145718A2 (fr) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprenant des acides aminés non endogènes et procédés de fabrication et d'utilisation associés
US10899834B2 (en) 2015-04-16 2021-01-26 H. Lundbeck A/S Anti-PACAP antibodies
KR102444717B1 (ko) 2016-04-15 2022-09-16 하. 룬드벡 아크티에셀스카브 인간화 항-pacap 항체 및 그의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU656230B2 (en) * 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
CA2379604A1 (fr) * 1999-09-28 2001-04-05 Bayer Corporation Recepteurs 3 agonistes (r3) pituitaire adenyl cyclase activateur de peptide (pacap) et leurs procedes pharmacologiques d'utilisation
WO2003068805A2 (fr) * 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Strategies de formulation dans la stabilisation de peptides dans des solvants organiques et a l'etat seche
PL377025A1 (pl) * 2002-07-12 2006-01-23 Bayer Pharmaceuticals Corporation Agoniści receptora peptydu aktywującego przysadkową cyklazę adenylową (PACAP) -VPAC2 i ich farmakologiczne sposoby zastosowania

Also Published As

Publication number Publication date
NO20063801L (no) 2006-10-26
US20090143283A1 (en) 2009-06-04
BRPI0507177A (pt) 2007-06-26
EP1713493A2 (fr) 2006-10-25
CA2554475A1 (fr) 2005-08-11
RU2006130691A (ru) 2008-03-10
EP1713493A4 (fr) 2009-06-24
KR20070009554A (ko) 2007-01-18
IL176705A0 (en) 2006-10-31
ECSP066793A (fr) 2006-11-16
WO2005072385A3 (fr) 2006-06-08
WO2005072385A2 (fr) 2005-08-11
JP2007519739A (ja) 2007-07-19
AU2005208911A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
Henning et al. Vasoactive intestinal peptide: cardiovascular effects
Deacon et al. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs
Larsen et al. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats
Brown et al. Brain peptide regulation of adrenal epinephrine secretion
Dogrukol-Ak et al. Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects
Banks The many lives of leptin
Cabou et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity
Ludvik et al. Amylin: history and overview
Bratusch-Marrain et al. Efficacy of pulsatile versus continuous insulin administration on hepatic glucose production and glucose utilization in type I diabetic humans
DE60016393T2 (de) Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe
Aronoff et al. Glucose metabolism and regulation: beyond insulin and glucagon
CN1487952A (zh) 具有血管活性肠肽的生物学活性的用于治疗肺动脉和小动脉高压的化合物
MA28335A1 (fr) Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes
Bray Food intake, sympathetic activity, and adrenal steroids
Uehlinger et al. Pressure dependence of atrial natriuretic peptide during norepinephrine infusion in humans.
JP2007534613A (ja) レラキシンスーパーファミリーペプチド類似体
Yokota et al. PACAP stimulates glucose output from the perfused rat liver
EP1976548A1 (fr) Fragments de vip et méthodes d'utilisation
Sanfield et al. Epinephrine increases plasma immunoreactive atrial natriuretic hormone levels in humans
Beglinger et al. Somatostatin and octreotide: physiological background and pharmacological application.
Gagliardino Physiological endocrine control of energy homeostasis and postprandial blood glucose levels
Patil et al. Role of insulin in management of type 2 diabetes mellitus
Ahrén et al. Interaction of vasoactive intestinal peptide (VIP) with cholinergic stimulation of glucagon secretion
Mueller et al. GIP potentiates CCK stimulated pancreatic enzyme secretion: correlation of anatomical structures with the effects of GIP and CCK on amylase secretion
Plamondon et al. Effects of central neuromedin B and related peptides on blood glucose